REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea flag South Korea · Delayed Price · Currency is KRW
9,870.00
-40.00 (-0.40%)
Aug 3, 2026, 3:30 PM KST

REYON Pharmaceutical Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
4,2906,66710,20924,10716,04966,741
Short-Term Investments
----20,00030,380
Trading Asset Securities
60.81115.036.05134.0219.83327.64
Cash & Short-Term Investments
4,3516,78210,21524,24136,06997,448
Cash Growth
-50.64%-33.61%-57.86%-32.79%-62.99%114.32%
Accounts Receivable
35,46334,38136,72039,92741,81040,465
Other Receivables
403.1299.59442.4450.98238.02384.38
Receivables
35,86634,68037,16239,97842,04840,850
Inventory
36,46637,93041,99135,17630,10926,432
Prepaid Expenses
49.0977.7528.03229.5728.5332.51
Other Current Assets
54.24195.1447.67188.61751.8941.89
Total Current Assets
76,78679,66589,44399,813109,006164,804
Property, Plant & Equipment
354,780361,230384,397368,342340,568281,156
Long-Term Investments
17,93618,93116,01121,21626,21124,557
Other Intangible Assets
1,0731,4801,8031,3921,4041,427
Long-Term Deferred Tax Assets
--4,4085,0754,1042,004
Long-Term Deferred Charges
2,8002,8002,8002,8002,8002,800
Other Long-Term Assets
1,008993.891,1311,137598.411,230
Total Assets
454,383465,100499,994499,776484,692477,978

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
6,1228,65910,0288,1864,7934,731
Accrued Expenses
3,3483,2693,5133,7763,6462,253
Short-Term Debt
106,877101,46481,20194,65622,50022,500
Current Portion of Long-Term Debt
16,00014,0008,0006,000--
Current Portion of Leases
705.03951.941,4581,6102,2541,911
Current Income Taxes Payable
---852.4733.48426.48
Other Current Liabilities
14,77914,98731,33610,52214,02515,682
Total Current Liabilities
147,831143,331135,537125,60247,95147,503
Long-Term Debt
95,00099,000113,000121,000184,218182,425
Long-Term Leases
590.78698.76392.91,7881,231478.19
Long-Term Deferred Tax Liabilities
237.27656.4665.8412.95-7.09
Other Long-Term Liabilities
1,1411,1411,0572,7483,5262,328
Total Liabilities
244,799244,827250,053251,151236,926232,741

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
9,2939,2939,2939,2938,9998,999
Additional Paid-In Capital
38,95538,95538,95538,95539,00339,003
Retained Earnings
167,027177,764207,397205,997205,151202,281
Treasury Stock
-5,079-5,079-5,078-5,079-5,079-5,079
Comprehensive Income & Other
-612.44-660.39-626-541.75-559.4-217.03
Total Common Equity
209,584220,273249,941248,625247,515244,987
Shareholders' Equity
209,584220,273249,941248,625247,765245,237
Total Liabilities & Equity
454,383465,100499,994499,776484,692477,978

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
219,173216,115204,053225,054210,203207,314
Net Cash (Debt)
-214,822-209,333-193,838-200,813-174,134-109,866
Net Cash Growth
------
Net Cash Per Share
-11659.67-11413.42-10552.84-10948.85-9538.14-6200.33
Filing Date Shares Outstanding
18.3418.3418.3418.3417.7517.75
Total Common Shares Outstanding
18.3418.3418.3418.3418.2517.75
Working Capital
-71,044-63,666-46,093-25,78961,055117,301
Book Value Per Share
11427.0712009.8713627.4613555.6813560.4313799.95
Tangible Book Value
208,511218,793248,138247,233246,111243,561
Tangible Book Value Per Share
11368.5711929.1713529.1513479.7913483.5113719.59
Land
12,36212,36212,36212,36212,36212,362
Buildings
209,537209,537209,53712,71212,71212,712
Machinery
169,670169,264166,01743,93942,51939,530
Construction In Progress
50,74149,55445,487342,022314,018256,737